E. Boven

发表

A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer.

O. Dalesio, I. B. Borel Rinkes, R. van Hillegersberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum Alpha-Fetoprotein Surge After the Initiation of Chemotherapy for Non-Seminomatous Testicular Cancer Has an Adverse Prognostic Significance

L. Collette, A. Oosterom, R. Sylvester, 1999 .

Cerebral Hyporesponsiveness and Cognitive Impairment Ten Years after Chemotherapy for Breast Cancer

D. Veltman, M. D. Ruiter, A. Nederveen, 2009, NeuroImage.

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

L. Collette, R. Sylvester, A. V. van Oosterom, 1998, British Journal of Cancer.

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1997, British Journal of Cancer.

Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method.

J. Hugtenburg, E. Swart, E. Boven, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

G. Jayson, T. Ganesan, P. Vasey, 2004, Gynecologic oncology.

Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.

W. W. ten Bokkel Huinink, O. van Tellingen, M. Hillebrand, 1995, Journal of chromatography. B, Biomedical applications.

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207).

J. Lemonnier, B. Thürlimann, H. Hawle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group.

J. Klijn, S. Fosså, R. Sylvester, 1990, European journal of cancer.

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer Hendricksen,

J. Witjes, T. Reijke, R. Puri, 2009 .

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer

S. Sleijfer, A. Jager, M. Jansen, 2023, Breast Cancer Research and Treatment.

Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".

M. Babjuk, T. D. de Reijke, M. Wirth, 2020, European urology.